Relief Therapeutics (RLFTF) Stock Price, News & Analysis

Company Overview

Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.

Key Stats

• Today's Range: $3.15 to $3.26
• 50-Day Range: $2.25 to $3.83
• 52-Week Range: $1.10 to $7.66
• Volume: 12,501 shs
• Average Volume: 3,277 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RLFTF Stock Analysis - Frequently Asked Questions

How have RLFTF shares performed this year?

Relief Therapeutics' stock was trading at $4.6552 on January 1st, 2025. Since then, RLFTF shares have decreased by 30.0% and is now trading at $3.26.
View the best growth stocks for 2025 here.

When did Relief Therapeutics' stock split?

Relief Therapeutics's stock reverse split before market open on Friday, May 5th 2023. The 1-400 reverse split was announced on Friday, May 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Relief Therapeutics?

Shares of RLFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RLFTF
• CIK: 1854078
• Web: www.relieftherapeutics.com
• Phone: N/A
• Fax: N/A
• Employees: 49
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A